1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited

ASTRAZEN.NS
AstraZeneca Pharma India LimitedIN flagNational Stock Exchange of India
8,236.00
INR
-74.50
- -
205.90BMarket Cap

Total Valuation

AstraZeneca Pharma India Limited carries a market capitalization of 205.90B, placing it among publicly traded companies globally. Its enterprise value stands at 190.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap205.90B
Enterprise Value190.66B

Share Statistics

AstraZeneca Pharma India Limited currently has 25.00M shares outstanding.

Shares Outstanding25.00M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

AstraZeneca Pharma India Limited trades at a trailing price-to-earnings ratio of 103.52. The price-to-sales ratio is 8.53, and the price-to-book ratio stands at 3,882.56.

PE Ratio103.52
PS Ratio8.53
PB Ratio3,882.56
P/TBV Ratio22.24
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, AstraZeneca Pharma India Limited trades at an EV/EBITDA multiple of 81.67 and an EV/FCF ratio of 5,711.01. The EV/Sales ratio of 8.38 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 81.67 provides insight into valuation relative to core operating earnings.

EV / Sales8.38
EV / EBITDA81.67
EV / EBIT81.67
EV / FCF5,711.01

Financial Position

AstraZeneca Pharma India Limited maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.68, indicating elevated leverage, while an interest coverage ratio of 51.99 demonstrates strong ability to service its debt obligations.

Current Ratio1.77
Quick Ratio0.47
Debt / Equity12.68
Debt / EBITDA0.47
Interest Coverage51.99

Financial Efficiency

AstraZeneca Pharma India Limited posts a return on equity of 58.35 and a return on invested capital of 19.47.

Return on Equity (ROE)58.35
Return on Assets (ROA)10.69
Return on Invested Capital (ROIC)19.47
Return on Capital Employed (ROCE)48.37
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.75

Taxes

Over the trailing twelve months, AstraZeneca Pharma India Limited has paid 646.80M in income taxes, reflecting an effective tax rate of 25.65.

Income Tax646.80M
Effective Tax Rate25.65

Stock Price Statistics

AstraZeneca Pharma India Limited's stock has declined approximately -9.99399% over the past 52 weeks. The 50-day moving average sits at 8,454.17, while the 200-day moving average is 8,707.29.

Beta (5Y)N/A
52-Week Price Change-9.99399%
50-Day Moving Average8,454.17
200-Day Moving Average8,707.29
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, AstraZeneca Pharma India Limited generated 22.76B in revenue and converted that into 1.88B in net income, yielding earnings per share of 75.01. EBITDA reached 2.33B, while operating income came in at 2.33B.

Revenue22.76B
Gross Profit8.95B
Operating Income2.33B
Pretax Income2.52B
Net Income1.88B
EBITDA2.33B
EBIT2.33B
Earnings Per Share (EPS)75.01

Balance Sheet

AstraZeneca Pharma India Limited holds 4.57B in cash and equivalents against 1.11B in total debt, resulting in a net debt position of -4.48B. Total book value stands at 50.00M, with working capital of 7.58B providing operational flexibility.

Cash & Cash Equivalents4.57B
Total Debt1.11B
Net Debt-4.48B
Equity (Book Value)50.00M
Book Value Per Share2.00
Working Capital7.58B

Margins

AstraZeneca Pharma India Limited operates with a gross margin of 39.33, reflecting its pricing power and cost economics. The operating margin of 10.26 and net profit margin of 8.24 provide insight into operational efficiency.

Gross Margin39.33
Operating Margin10.26
Pretax Margin11.08
Profit Margin8.24
EBITDA Margin10.26

Stock Splits

AstraZeneca Pharma India Limited's most recent stock split took place on June 15, 2006 with a 1:5 split ratio.

Last Split Date6/15/2006
Split Ratio1:5

Scores

AstraZeneca Pharma India Limited posts an Altman Z-Score of 12.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score12.42